

NHS Foundation Trust

Information Governance Department

Suite 9 Buckingham Row Brick Kiln Lane Wigan WN1 1XX

Email: foi@wwl.nhs.uk Web: www.wwl.nhs.uk

Ref: FOI/2025/10572

Date Received: 5th March 2025

Response Due: 2nd April 2025

Date: 24th March 2025

Dear Sir/Madam

With reference to your request for information received on 5th March 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do not hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of October 2024 to the end of December 2024, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the

3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available?

Name of medicine		Number patients treated
1.1 Abemaciclib (Verzenios)		
1.2 Alpelisib (Piqray)		Please see the
1.3 Elacestrant (Orserdu)		suggested redirection below.
1.4 Fulvestrant (fulvestrant or Faslodex)		
1.5 Inavolisib (Inaqovi)		

1.6 Palbociclib (Ibrance)	
1.7 Ribociclib (Kisqali)	
1.8 Capivasertib (Truqap)	
1.9 Talazoparib (Talzenna)	
1.10 Olaparib (Lynparza)	

Q2. How many patients received the following medicines for <u>early breast cancer</u> in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	Please see the
2.2 Ribociclib (Kisqali)	suggested redirection
2.3 Olaparib (Lynparza)	below.

Q3. How many patients received the following medicines with <u>curative</u> treatment intent in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	Please see the
3.2 Ribociclib (Kisqali)	suggested redirection below.

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	Please see the suggested redirection below.
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	below.

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of October 2024 to the end of December 2024?

Type of breast cancer	
5.1 All types of breast cancer	
5.2 Locally advanced or metastatic breast cancer	

Number patients treated

Please see the suggested redirection below.

The Trust refers any patients requiring oncology treatment to the Christies. Therefore, please redirect your Freedom of Information request to <u>the-christie.foi@nhs.net</u>

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

d.d Q

Hazel Hendriksen Divisional Director of Operations for Specialist Services

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire, SK9 5AF

Helpline number: 0303 123 111